The recurring revenue story behind Serina Therapeutics SER Q4 2025 EPS Exceeds Expectations The surprise hidden in Annaly NLYI last earnings report NLYI Annaly Series I Preferred Declares Dividend How UiPath PATH performance compares to expectations Weakens 20260506 HSAI Hesai shares climb 638 percent despite Q4 2025 earnings per share missing analyst forecasts FINV Q1 2026 Earnings EPS of 1764126 Drives Stock Surge Despite Missing Revenue Context Armata Pharmaceuticals ARMP Q1 2026 Earnings Massive EPS Miss as PreRevenue Biotech Struggles with Costs INCR Q2 2023 Earnings EPS Surges Past Estimates as Profitability Strengthens ABTC Q1 2026 Earnings Earnings Miss Amid Significant EPS Surprise Revenue Absent GitLab Q1 2026 Earnings EPS Beat Drives Stock Uptick HSDT Q1 2026 Earnings Significant EPS Miss Raises Concerns Adient Q1 2026 Earnings Earnings Beat Drives Stock Higher Amid Mixed Operational Signals BMNR Q1 2026 Earnings Positive EPS Surprise Amidst Modest Operational Disclosure KELYB Q1 2026 Earnings Significant EPS Miss Amid Challenging Environment ATA Creativity Global American Depositary Shares Q3 2024 Earnings EPS Reflects Continuing Losses Amid Speculative Stock Movement Expion360 Q2 2025 Earnings EPS Surpasses Estimates as Narrower Loss Signals Cost Discipline APEI Q1 2026 Earnings EPS Surges Past Estimates by 38 Yet Stock Slips WHLR Q2 2024 Earnings EPS of 365 Strengthens as Stock Declines 136